ProKidney Corp
PROK
查看详细走势图
1.870USD
+0.140+8.09%
收盘 02/06, 16:00（美东）报价延迟15分钟
254.28M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.09%
5天
-5.56%
1月
-22.73%
6月
-27.10%
今年开始到现在
-16.52%
1年
+19.87%
查看详细走势图
TradingKey ProKidney Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
ProKidney Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名160/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.71。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
ProKidney Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
ProKidney Corp亮点
亮点风险
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
业绩增长期
公司处于发展阶段，最新年度总收入76.00K美元
估值合理
公司最新PE估值-3.41，处于3年历史合理位
机构减仓
最新机构持股41.07M股，环比减少6.40%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值10.21K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.16
分析师目标
根据
9
位分析师
买入
评级
6.714
目标均价
+253.38%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ProKidney Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ProKidney Corp简介
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
公司代码PROK
公司ProKidney Corp
CEOCulleton (Bruce)
网址https://prokidney.com/
相关品种
